280 related articles for article (PubMed ID: 24650703)
1. Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function.
Field JJ; Kanakkanthara A; Miller JH
Bioorg Med Chem; 2014 Sep; 22(18):5050-9. PubMed ID: 24650703
[TBL] [Abstract][Full Text] [Related]
2. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
3. A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment.
Fürst R; Vollmar AM
Pharmazie; 2013 Jul; 68(7):478-83. PubMed ID: 23923626
[TBL] [Abstract][Full Text] [Related]
4. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
5. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.
Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA
Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056
[TBL] [Abstract][Full Text] [Related]
6. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
Tinley TL; Randall-Hlubek DA; Leal RM; Jackson EM; Cessac JW; Quada JC; Hemscheidt TK; Mooberry SL
Cancer Res; 2003 Jun; 63(12):3211-20. PubMed ID: 12810650
[TBL] [Abstract][Full Text] [Related]
7. [Progress in the study of tubulin inhibitors].
Shang H; Pan L; Yang S; Chen H; Cheng MS
Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
[TBL] [Abstract][Full Text] [Related]
8. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
Kanakkanthara A; Teesdale-Spittle PH; Miller JH
Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
Ohira M; Iwasaki Y; Tanaka C; Kuroki M; Matsuo N; Kitamura T; Yukuhiro M; Morimoto H; Pang N; Liu B; Kiyono T; Amemiya M; Tanaka K; Yoshida K; Sugimoto N; Ohshima T; Fujita M
Biochim Biophys Acta; 2015 Sep; 1850(9):1676-84. PubMed ID: 25960391
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative Activity of Crocin Involves Targeting of Microtubules in Breast Cancer Cells.
Hire RR; Srivastava S; Davis MB; Kumar Konreddy A; Panda D
Sci Rep; 2017 Mar; 7():44984. PubMed ID: 28337976
[TBL] [Abstract][Full Text] [Related]
11. PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.
Martínez-Díez M; Guillén-Navarro MJ; Pera B; Bouchet BP; Martínez-Leal JF; Barasoain I; Cuevas C; Andreu JM; García-Fernández LF; Díaz JF; Avilés P; Galmarini CM
Biochem Pharmacol; 2014 Apr; 88(3):291-302. PubMed ID: 24486569
[TBL] [Abstract][Full Text] [Related]
12. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation.
Mohan R; Banerjee M; Ray A; Manna T; Wilson L; Owa T; Bhattacharyya B; Panda D
Biochemistry; 2006 May; 45(17):5440-9. PubMed ID: 16634625
[TBL] [Abstract][Full Text] [Related]
13. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine.
Jordan MA; Horwitz SB; Lobert S; Correia JJ
Semin Oncol; 2008 Jun; 35(3 Suppl 3):S6-S12. PubMed ID: 18538179
[TBL] [Abstract][Full Text] [Related]
14. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
Mooberry SL; Leal RM; Tinley TL; Luesch H; Moore RE; Corbett TH
Int J Cancer; 2003 Apr; 104(4):512-21. PubMed ID: 12584751
[TBL] [Abstract][Full Text] [Related]
15. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.
Arnst KE; Banerjee S; Chen H; Deng S; Hwang DJ; Li W; Miller DD
Med Res Rev; 2019 Jul; 39(4):1398-1426. PubMed ID: 30746734
[TBL] [Abstract][Full Text] [Related]
16. Microtubule disassembly and inhibition of mitosis by a novel synthetic pharmacophore.
Scaife RM
J Cell Biochem; 2006 May; 98(1):102-14. PubMed ID: 16365878
[TBL] [Abstract][Full Text] [Related]
17. Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs.
Brunden KR; Lee VM; Smith AB; Trojanowski JQ; Ballatore C
Neurobiol Dis; 2017 Sep; 105():328-335. PubMed ID: 28012891
[TBL] [Abstract][Full Text] [Related]
18. Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability.
Wu J; He Z; Wang DL; Sun FL
Cell Cycle; 2016 Nov; 15(21):2980-2991. PubMed ID: 27715397
[TBL] [Abstract][Full Text] [Related]
19. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest.
Mohan R; Panda D
Cancer Res; 2008 Aug; 68(15):6181-9. PubMed ID: 18676841
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitors of microtubule polymerization- new natural compounds as potential anti-cancer drugs].
Rogalska A; Miśkiewicz K; Marczak A
Postepy Hig Med Dosw (Online); 2015 May; 69():571-85. PubMed ID: 25983296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
